[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Schmidt D: [Endometrial carcinomas and precursor lesions--new aspects]. Pathologe; 2009 Jul;30(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial carcinomas and precursor lesions--new aspects].
  • Endometrial carcinomas can be separated into two groups which are designated as type I and type II carcinomas today.
  • Only type I carcinomas are associated with hyperestrogenism.
  • The group of type I carcinomas consists of endometrioid carcinoma and its variants, and mucinous carcinoma.
  • The prototypes of type II carcinomas are serous and clear cell carcinoma.
  • Not all carcinomas, however, can be assigned to one of the two groups, because there are hybrid tumors and mixed carcinomas, e.g. endometrioid carcinoma with a serous component.
  • The precursor lesions of the endometrioid carcinoma and the serous carcinoma are well characterized morphologically and by molecular pathology.
  • Atypical hyperplasia is the precursor lesion of endometrioid carcinoma, whereas endometrial intraepithelial carcinoma (EIC) is the precursor lesion of serous carcinoma.
  • No precursor lesion has as yet been identified for clear cell carcinoma.
  • Immunohistochemical markers for endometrial carcinoma are CK7 and vimentin, for serous carcinoma markers are p53 and p16.
  • Correct typing is of essential prognostic necessity in endometrial carcinoma.
  • Of utmost importance is the detection of a serous component, because serous carcinoma leads to early tumor spread with the necessity of radical surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Biomarkers / analysis. Carcinoma / pathology. Female. Humans. Hyperplasia. Menopause. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Vimentin / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124 Suppl:S42-51 [16468417.001]
  • [Cites] Pathology. 2007 Feb;39(1):134-8 [17365829.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):145-84 [11981113.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):279-289 [11494005.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):434-40 [9277658.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):569-75 [8179072.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):769-74 [7793474.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):348-53 [15086736.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):328-33 [17581420.001]
  • [Cites] Pathol Res Pract. 1992 Oct;188(7):856-9 [1448376.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):157-66 [15644772.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17 (2):129-34 [9553809.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1740-7 [8859187.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):463-9 [14675663.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):37-42 [19116629.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19495762.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


2. Poonawalla T, Uchida T, Diven DG: Survey of antibiotic prescription use for inflamed epidermal inclusion cysts. J Cutan Med Surg; 2006 Mar-Apr;10(2):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Symptomatic epidermal inclusion cysts (EICs) are variously called "inflamed" or "infected," and the mechanism of inflammation or suppuration is controversial.
  • Whether physicians routinely prescribe antibiotics for inflamed EICs is of concern owing to cost and bacterial resistance.
  • OBJECTIVES: To determine whether there is any difference in the diagnosis and treatment of EICs between primary care physicians and dermatologists and to estimate the rate and cost of antibiotic prescriptions for EICs.
  • Eighty-four percent of the general practitioners and 94% of the dermatologists chose antibiotics for treatment.
  • CONCLUSION: This study shows that despite the differences between general practitioners and dermatologists in diagnosis, the majority of physicians use antibiotics for the treatment of inflamed EICs.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Drug Prescriptions / statistics & numerical data. Epidermal Cyst / drug therapy. Practice Patterns, Physicians' / statistics & numerical data
  • [MeSH-minor] Humans. Inflammation / drug therapy. Texas

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241579.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


3. Sauer R, Schulz KD, Hellriegel KP, Deutsche Gesellschaft für Senologie]: [Radiation therapy after mastectomy--interdisciplinary consensus puts and end to a controversy. German Society of Senology]. Strahlenther Onkol; 2001 Jan;177(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiation therapy after mastectomy--interdisciplinary consensus puts and end to a controversy. German Society of Senology].
  • BACKGROUND: Recent publications of the Danish Breast Cancer Cooperative Group together with data from the British Columbia Trial have stirred major discussions concerning the role of radiation therapy after mastectomy.
  • Different treatment approaches are to be found even within the same cancer center.
  • The German Society of Senology, a cooperative group of all medical disciplines involved in the treatment of breast cancer, has therefore worked out a consensus statement.
  • MATERIAL AND METHOD: The recently published literature and experts opinions, in particular randomized studies since 1997, meta-analyses from the Early Breast Cancer Trialists' Collaborative Group, epidemiological investigations with regard to the time course of distant metastases in breast cancer as well as the current consensus of the American Society for Therapeutic Radiology and Oncology served as the basis for discussion and consulting.
  • If axillary lymph nodes are involved, the surgical removal of these lymph nodes is not only of diagnostic, but also of therapeutic value, as it reduces the risk for locoregional relapses. (2) Most probably, locoregional relapses do not only indicate, but are also a source for distant metastases. (3) Radiation therapy of the chest wall and the regional lymph nodes increases the overall survival in risk patients and reduces the risk of locoregional relapses.
  • Moreover, radiation therapy improves the prognosis in case of residual tumor or an incomplete axillary dissection.
  • Unequivocal and reasonable indications for radiation therapy after mastectomy include T3/T4-carcinoma, T2-carcinoma > 3 cm, multicentric tumor growth, lymphangiosis carcinomatosa or vessel involvement, involvement of the pectoralis fascia or a safety margin < 5 mm, R1- or R2 resection and more than 3 axillary lymph node metastases.
  • Further reasonable indications, albeit not yet evaluated in clinical trials, include multifocality, extensive intraductal component, negative hormone receptor status, G3-differentiation grade, diffuse micro-calcifications, 1 to 3 axillary lymph node metastases, multiple, non-complete biopsies and age < 35 years. (4) An endocrine therapy with tamoxifen concurrent to radiation therapy is also reasonable--despite some contradictory in-vitro data--as it enhances the apoptotic cell death.
  • The CMF-regimen is usually performed as sandwich procedure, but can also be applied concurrently to radiation therapy, if indicated.
  • Conversely, an anthracycline-containing chemotherapy should be finished prior to postoperative radiation therapy.
  • CONCLUSIONS: Adjuvant radiation therapy after mastectomy improves the 10-year-survival probability up to 10%, at least for risk patients.
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200107.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


Advertisement
4. Akashi-Tanaka S, Fukutomi T, Sato N, Miyakawa K: The role of computed tomography in the selection of breast cancer treatment. Breast Cancer; 2003;10(3):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of computed tomography in the selection of breast cancer treatment.
  • Contrast-enhanced computed tomography (CE-CT) is one of the most sensitive imaging modalities.
  • (1) to determine the extent of breast cancer to select the appropriate breast conserving treatment (BCT).
  • The sensitivity and specificity for the detection of extensive intraductal component (EIC) by CE-CT were 82-88% and 75-89%, respectively.
  • (2) to determine the extent of resection following neoadjuvant chemotherapy, which is difficult to assess by other modalities;.
  • [MeSH-major] Breast Neoplasms / radiography. Tomography, X-Ray Computed / standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12955031.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 32
  •  go-up   go-down


5. Allard JE, Risinger JI, Morrison C, Young G, Rose GS, Fowler J, Berchuck A, Maxwell GL: Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol; 2007 Oct;107(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Oligonucleotide array and tissue microarray analysis (TMA) by our group has revealed that folate binding protein (FOLR1) is overexpressed in some types of uterine cancer, particularly tumors with serous histology.
  • Since FOLR1 overexpression is a frequent event in some types of endometrial carcinoma, we examined the relationship between FOLR1 overexpression and clinical and pathologic features to determine its prognostic relevance.
  • METHODS: A tissue microarray (TMA) comprised of primary tumor specimens from 485 patients diagnosed with endometrial adenocarcinoma was used to identify cases characterized by FOLR1 overexpression.
  • RESULTS: Overexpression of FOLR1 was observed in 50/292 (17%) cases and was seen more often in poorly differentiated cancers (22/90 [24%], p=0.051) and tumors with serous histology (16/32 [50%], p<0.001).
  • A shorter progression-free survival was noted in patients with FOLR1 overexpression (log-rank p=0.016) that persisted when the data were limited to patients with stage III/IV disease (log-rank p=0.021) or serous tumors (log-rank p=0.020).
  • 2.14; 95% CI 1.07-4.28) even when controlling for stage, grade, myometrial invasion and adjuvant chemotherapy.
  • CONCLUSIONS: Our data show that FOLR1 overexpression is not only a biomarker associated with endometrial cancer, but it also appears to be a prognostic factor associated with adverse outcome.
  • These findings suggest that FOLR1 may be an appealing target for biological therapies in some types of endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carrier Proteins / metabolism. Disease-Free Survival. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Receptors, Cell Surface / metabolism. Survival Rate
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Folate Receptor 1. Folate Receptors, GPI-Anchored. Humans. Middle Aged. Prognosis. Tissue Array Analysis. Uterine Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582475.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FOLR1 protein, human; 0 / Folate Receptor 1; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  •  go-up   go-down


6. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J, Wadehra M: Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res; 2010 Aug 1;16(15):3954-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.
  • PURPOSE: The tetraspan protein epithelial membrane protein-2 (EMP2) has been shown to regulate the surface display and signaling from select integrin pairs, and it was recently identified as a prognostic biomarker in human endometrial cancer.
  • EXPERIMENTAL DESIGN: We examined the expression of EMP2 within a population of women with ovarian cancer using tissue microarray assay technology.
  • We evaluated the efficacy of EMP2-directed antibody therapy using a fully human recombinant bivalent antibody fragment (diabody) in vitro and ovarian cancer xenograft models in vivo.
  • RESULTS: EMP2 was found to be highly expressed in >70% of serous and endometrioid ovarian tumors compared with nonmalignant ovarian epithelium using a human ovarian cancer tissue microarray.
  • Treatment of human ovarian cancer cell lines with anti-EMP2 diabodies induced cell death and retarded cell growth, and these response rates correlated with cellular EMP2 expression.
  • We next assessed the effects of anti-EMP2 diabodies in mice bearing xenografts from the ovarian endometrioid carcinoma cell line OVCAR5.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] FASEB J. 2004 Jan;18(1):206-8 [14597555.001]
  • [Cites] Clin Immunol. 2003 May;107(2):129-36 [12763482.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2073-83 [14978215.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jun;53(6):497-509 [14648071.001]
  • [Cites] Protein Eng Des Sel. 2004 Apr;17(4):315-23 [15187222.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Sep;31(3):309-16 [15205179.001]
  • [Cites] J Biopharm Stat. 2004 Aug;14(3):671-85 [15468758.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Nature. 1982 Jan 14;295(5845):116-9 [6173755.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1201-9 [15555554.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1032-42 [15564135.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 7;326(1):218-27 [15567174.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Blood. 2005 Jan 15;105(2):562-6 [15374889.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):131-41 [15942652.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jul 15;239(1-2):15-26 [15955618.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1605-16 [16227411.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):336-45 [16216233.001]
  • [Cites] Dev Biol. 2006 Apr 15;292(2):430-41 [16487956.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):90-8 [16736513.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1583-91 [16949910.001]
  • [Cites] Radiol Clin North Am. 2007 Jan;45(1):149-66 [17157627.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2007 Jul;16(4):353-8 [17565278.001]
  • [Cites] Immunol Res. 2007;39(1-3):271-8 [17917071.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6056-63 [17947468.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10484-90 [17974992.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):351-6 [18395030.001]
  • [Cites] Reprod Biol Endocrinol. 2008;6:15 [18400107.001]
  • [Cites] Ann Oncol. 2008 Sep;19 Suppl 7:vii61-6 [18790981.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7367-77 [19010852.001]
  • [Cites] Methods Mol Biol. 2009;472:413-37 [19107446.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Jan;50(1):462-9 [18469192.001]
  • [Cites] Nat Rev Drug Discov. 2008 Sep;7(9):747-58 [18758472.001]
  • [Cites] FEMS Immunol Med Microbiol. 2009 Mar;55(2):240-9 [19159428.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1619-28 [19349354.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3890-5 [11389031.001]
  • [Cites] Cancer Gene Ther. 2001 Aug;8(8):555-65 [11571533.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41094-100 [12189152.001]
  • [Cites] Exp Mol Pathol. 2003 Apr;74(2):106-12 [12710941.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • (PMID = 20670949.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016042; United States / NCI NIH HHS / CA / U24 CA086366; United States / NICHD NIH HHS / HD / R03 HD048540; United States / NCI NIH HHS / CA / R21 CA131756; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / NCI CA-86366; United States / NCI NIH HHS / CA / U54 CA119367; United States / NCI NIH HHS / CA / R21 CA131756-01A1; United States / NCI NIH HHS / CA / CA131756-01A1; United States / NICHD NIH HHS / HD / HD48540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EMP2 protein, human; 0 / Immunoglobulin Fragments; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ NIHMS211285; NLM/ PMC2913478
  •  go-up   go-down


7. Kang DK, Kim EJ, Kim HS, Sun JS, Jung YS: Correlation of whole-breast vascularity with ipsilateral breast cancers using contrast-enhanced MDCT. AJR Am J Roentgenol; 2008 Feb;190(2):496-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred three of these 143 patients were finally enrolled in the study after exclusion of patients with bilateral breast cancer, previous history of neoadjuvant chemotherapy, breast surgery, or lack of surgical confirmation.
  • Breast vascularity was then correlated to prognostic factors including tumor size, lymph node status, cancer stage, nuclear and histologic grade, presence of an extensive intraductal component, presence of hormone receptors, and expression of C-erb-B2.
  • The presence of extensive intraductal component and hormone receptors and the expression of C-erb-B2 were not related to ipsilateral increased vascularity.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / radiography. Neovascularization, Pathologic / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212238.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF: Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol; 2006 Nov;13(11):1443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
  • BACKGROUND: Residual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning.
  • METHODS: Tumor size was evaluated by physical examination, mammography, and sonography at diagnosis and before surgery in 162 breast cancer patients who received neoadjuvant chemotherapy.
  • The effect of invasive lobular carcinoma, high nuclear grade, hormone receptor positivity, and the presence of an extensive intraductal component on the accuracy of mammography and sonography in predicting pathologic residual tumor size was analyzed.
  • Multivariate analysis showed that pathologic residual tumor size was underestimated for lobular carcinoma and overestimated for poorly differentiated tumors.
  • CONCLUSIONS: The combination of mammography and sonography has a high accuracy in predicting pCR after neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / drug therapy. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028770.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


9. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer; 2002 Jan-Feb;12(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metallothioneins (MTs) are a group of low-molecular-weight proteins that are overexpressed in a variety of human neoplasms and are related to differentiation and prognosis in some tumor types.
  • This study investigated immunohistochemically detectable metallothionein expression in benign and malignant ovarian surface epithelial tumors of serous, mucinous, and endometrioid types.
  • MT expression was observed in 56% of carcinomas (n = 139) and in 2% of benign neoplasms (n = 81).
  • Of the malignant tumors, MT expression was found in 68% of endometrioid, 56% of mucinous, and 52% of serous neoplasms.
  • There was increased MT expression in grade 3 carcinomas (64%) as compared with grade 2 (60%) and grade 1 (23%).
  • The overexpression of MT in malignant as opposed to benign ovarian surface epithelial tumors may suggest a role in tumorigenesis.
  • Analogous to the situation in endometrial carcinomas, there is a tendency toward higher expression in poorly differentiated tumors.
  • Whether high MT expression is an independent prognostic factor and increased expression indicates chemotherapy resistance in ovarian cancer, as has been previously suggested, should be determined by further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860537.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


10. Perez CA: Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities. Cancer J; 2003 Nov-Dec;9(6):442-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities.
  • PURPOSE: To assess the significance of patient age, race, tumor-related prognostic parameters, status of surgical excision margins, and irradiation boost on incidence of ipsilateral breast relapse, and to review current issues in the management of T1-T2 breast cancer patients with conservation therapy.
  • MATERIALS AND METHODS: Records of 1037 patients with histologically confirmed stage T1 and 308 patients with T2 carcinoma of the breast treated with breast conservation therapy from January 1970 through December 1997 were prospectively registered and evaluated.
  • In patients 40 years of age or younger, four of 24 (17%) with extensive intraductal component developed an ipsilateral breast relapse, compared with six of 80 (8%) without extensive intraductal component, in contrast to eight of 159 (5%) and 33 of 776 (4%) in postmenopausal patients with or without extensive intraductal component, respectively.
  • In patients with T2 tumors, two of eight (25%) women 40 years or younger with extensive intraductal component, and seven of 50 (14%) without extensive intraductal component developed ipsilateral breast relapse.
  • In patients with positive margins, the relapse rate was 4% in 215 receiving a boost (18-20 Gy) and 33% (two of six) without a boost.
  • In T1 tumors, the breast failure rate was two of 53 (3.7%) in women < or = 40 years receiving chemotherapy and eight of 51 (15.6%) without chemotherapy.
  • On multivariate analysis, only age and adjuvant therapy were significant factors predictive of ipsilateral breast relapse.
  • CONCLUSIONS: Surgical excision margins status following adequate doses of radiation therapy was not a predictor of ipsilateral breast relapse.
  • In patients younger than 40 years of age with extensive intraductal component, a somewhat higher breast relapse rate was noted but not enough to preclude breast conservation therapy.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal / surgery. Mastectomy, Segmental / trends. Neoplasm Recurrence, Local / epidemiology


11. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


12. Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z: Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Arch Iran Med; 2007 Apr;10(2):258-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma.
  • Herein, we reported a patient with papillary serous carcinoma arising from adenomyosis.
  • The patient was a 61-year-old woman who received tamoxifen for treatment of her breast cancer over the past five years.
  • In one of these foci, papillary serous carcinoma was found.
  • No evidence of tumor was seen in endometrial surface, peritoneum, and both adnexa.
  • [MeSH-major] Carcinoma, Papillary / pathology. Endometriosis / pathology. Leiomyoma / diagnosis. Myometrium / pathology. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Atrophy. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Tamoxifen / therapeutic use


13. Hetelekidis S, Schnitt SJ, Silver B, Manola J, Bornstein BA, Nixon AJ, Recht A, Gelman R, Harris JR, Connolly JL: The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys; 2000 Jan 1;46(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate if extracapsular extension (ECE) of axillary lymph node metastases predicts for a decreased rate of disease-free survival or an increased rate of regional recurrence of breast carcinoma.
  • METHODS: The study population consisted of 368 patients with T1 or T2 breast cancer and pathologically-positive lymph nodes treated with breast-conserving therapy between 1968 and 1986.
  • Median follow-up time for the surviving patients was 139 months (range 70-244).
  • Twenty percent of the patients were treated with supraclavicular RT, and 64% received both axillary and supraclavicular RT, with a median dose to the nodes of 45 Gy.
  • The following factors were evaluated: presence of ECE, number of sampled lymph nodes (LN), number of involved LN, size of primary tumor, histologic grade of tumor, presence of lymphatic vessel invasion (LVI), presence of an extensive intraductal component (EIC), radiation dose, use of adjuvant chemotherapy, and age of patient.
  • [MeSH-minor] Axilla. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10656369.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Hatano K, Yokota Y, Hanaki H, Sunakawa K: [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)]. Kansenshogaku Zasshi; 2006 May;80(3):243-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, the survival rate with combination therapy consistings IPM/CS plus teicoplanin (T EIC) was significantly higher, and the number of residual viable cells in the kidney was significantly lower, than with TEIC monotherapy alone.
  • In the mice with pneumonia, the number of residual viable cells in the lung after combination therapy with IPM/CS and TEIC was significantly lower than with TEIC monotherapy.
  • Combination therapy with beta-lactams plus VCM showed antagonistic in models of systemic infection and pulmonary infection caused by BIVR, whereas combination therapy consisting of a beta-lactam plus TEIC had a synergistic effect in the same models, even though VCM and TEIC are member of the same glycopeptide antibiotic class.
  • [MeSH-major] Staphylococcal Infections / drug therapy. Staphylococcus aureus / drug effects. Teicoplanin / administration & dosage. Vancomycin / administration & dosage. Vancomycin / antagonists & inhibitors. beta-Lactams / administration & dosage. beta-Lactams / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Resistance, Multiple, Bacterial. Male. Methicillin Resistance. Mice. Mice, Inbred ICR

  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780131.001).
  • [ISSN] 0387-5911
  • [Journal-full-title] Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases
  • [ISO-abbreviation] Kansenshogaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / beta-Lactams; 61036-62-2 / Teicoplanin; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


15. Yuan J, Zhang Z, Xiao JY: [Efficacy of radiotherapy combined with Traditional Chinese medicine (TCM) in NPC patients]. Hunan Yi Ke Da Xue Xue Bao; 2000 Jun 28;25(3):254-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From January 1992 to November 1994, 163 patients with nasopharyngeal carcinoma (NPC) were prospectively randomized into three groups: standard radiotherapy (SRT) group, external irradiation and after-load intracavitary radiation in combination with traditional Chinese medicine (EIAIRC) group, and external irradiation plus traditional Chinese medicine (EIC) group.
  • The nasopharynx's radiation dose was 50-60 Gy, intracavitary irradiation 16 Gy/2 times (The distance from radiation source to spot of reference was 14 mm away).
  • The radiation dose in EIC and SRT group was 68-72 Gy, respectively.
  • It indicates that the therapy might decrease radiation dose and the TCM does not induce NPC distant metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Cobalt Radioisotopes / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Nasopharyngeal Neoplasms / radiotherapy. Phytotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Female. Humans. Male. Middle Aged. Plants, Medicinal. Survival Rate

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212157.001).
  • [ISSN] 1000-5625
  • [Journal-full-title] Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University
  • [ISO-abbreviation] Hunan Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Drug Combinations; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


16. Houvenaeghel G, Lambaudie E, Buttarelli M, Cohen M, Bannier M, Tallet A, Jacquemier J: [Margin status in invasive breast cancer]. Bull Cancer; 2008 Dec;95(12):1161-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several predictive factors for local recurrence have been identified and some of them such as margins of resection, radiation therapy, chemotherapy, and hormonotherapy can be modified.
  • The influence of extensive intraductal component on local recurrence risk has been studied.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Ductal, Breast / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091649.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


17. Smitt MC, Nowels K, Carlson RW, Jeffrey SS: Predictors of reexcision findings and recurrence after breast conservation. Int J Radiat Oncol Biol Phys; 2003 Nov 15;57(4):979-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To identify predictors of reexcision findings and local recurrence in the setting of breast-conserving therapy with radiation.
  • However, the use and sequencing of systemic therapy affected recurrence rates among these patients.
  • For patients with close, positive, or indeterminate margins, the crude risk of local recurrence was 4% among patients who received tamoxifen or received chemotherapy integrated with or after radiation.
  • The risk of local recurrence was 16-29% among the patients with close, positive, or indeterminate margins who did not receive systemic therapy or who received radiation after completion of chemotherapy.
  • Local recurrence rates were low in patients with negative margins (2-8%) regardless of the use of systemic therapy or its timing.
  • Among patients who underwent reexcision before radiation, extensive intraductal component (EIC) (p = 0.0001) and young patient age (p = 0.03) were predictive of residual disease in the specimen.
  • Patients with initially close margins and no EIC had a low risk of residual disease at the time of reexcision, as did patients older than age 65 without EIC.
  • Patient age and EIC were significant predictors of residual disease at reexcision.
  • The use and timing of systemic therapy appear to influence the risk of local recurrence in patients who do not have negative lumpectomy margins.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Multivariate Analysis. Neoplasm, Residual. Reoperation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14575828.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M: An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer. Breast Cancer; 2002;9(2):145-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer.
  • BACKGROUND: The usefulness of primary chemotherapy has been widely recognized and applied to routine clinical practice to improve prognosis by downstaging.
  • Nevertheless, none of many trials has been able to show a positive effect of primary chemotherapy in terms of prognosis, and predictive factors of outcome have not been defined and are still under investigation.
  • METHODS: Primary chemotherapy was given to 50 patients with advanced breast cancer.
  • Predictive factors involved in clinical or pathological response to primary chemotherapy (3 cycles of CE(F) therapy ) were investigated.
  • MIB-1 was related to the clinical response and EIC (extensive intraductal component) was related to the pathological response; the response was high in patients with EIC negative tumors.
  • Responders had tumors with higher proliferative activity, which decreased significantly after chemotherapy.
  • Patients with a decrease of more than 30% in proliferative activity after chemotherapy had significantly higher disease-free survival rates.
  • CONCLUSION: The proliferative activity and EIC status were useful predictors of clinical or pathological response to primary chemotherapy.
  • A decrease in proliferative activity by chemotherapy significantly correlated with clinical response and reflected a favorable prognosis.
  • The number of patients benefiting from primary chemotherapy might steadily increase by detecting these predictive factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Cyclophosphamide / administration & dosage. Cytarabine. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Logistic Models. Mastectomy, Segmental / methods. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Probability. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016394.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CEF regimen
  •  go-up   go-down


19. Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicolaou N: Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol; 2002 Oct 1;20(19):4015-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Recursive partitioning analysis (RPA), a method of building decision trees of significant prognostic factors for outcome, was used to determine subgroups at significantly different risk for ipsilateral breast tumor recurrence (IBTR) in early-stage breast cancer.
  • Systemic therapy was chemotherapy with or without tamoxifen in 32%, tamoxifen in 27%, or none in 41%.
  • RPA was used to create a decision tree according to predictive variables that classify patients by IBTR risk, and the Kaplan-Meier method was used to calculate 10-year risks.
  • For patients </= 55 years old, extensive intraductal component (EIC) was the next significant split.
  • For EIC-negative tumors, age </= 35 years and negative margins were associated with a 10-year IBTR of 3%; with close (</= 2 mm) or positive margins, 34%.
  • Patients </= 35 years old had a low risk of IBTR when tumors were EIC-negative with negative margins.
  • EIC was an independent factor for IBTR for ages </= 55 years.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Actuarial Analysis. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Decision Trees. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Prognosis. Risk Assessment. Tamoxifen / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol 2002 Dec 15;20(24):4727. Nicoloau N [corrected to Nicolaou N]
  • (PMID = 12351599.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


20. Schwartz PE: The management of serous papillary uterine cancer. Curr Opin Oncol; 2006 Sep;18(5):494-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of serous papillary uterine cancer.
  • PURPOSE OF REVIEW: Uterine papillary serous cancer is an extremely aggressive cancer, the optimum management of which is still being determined.
  • RECENT FINDINGS: The main themes in the literature regarding uterine papillary serous cancer are that a potential precursor lesion, serous endometrial intraepithelial carcinoma, has been recognized as an early form of the disease.
  • A variety of molecular biologically important markers have now been identified, including p53, HER2/neu, IL-6, kallikrein 6, and claudin-4, some of which may be susceptible to molecularly targeted therapy.
  • Systematic surgical staging is necessary before additional therapy is recommended.
  • Stage I uterine papillary serous cancer requires aggressive treatment, including surgery, chemotherapy, and radiation therapy for successful treatment.
  • SUMMARY: Serous endometrial intraepithelial carcinoma should be treated as a form of uterine papillary serous cancer.
  • Multimodality therapy is required for the successful management of early stage uterine papillary serous cancer.
  • Advanced disease is often unresponsive to conventional therapy.
  • Molecularly targeted therapies are now being introduced into the management of this disease.
  • [MeSH-major] Carcinoma, Papillary / therapy. Endometrial Neoplasms / therapy. Uterine Neoplasms / therapy


21. Perera F, Yu E, Engel J, Holliday R, Scott L, Chisela F, Venkatesan V: Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up. Int J Radiat Oncol Biol Phys; 2003 Dec 1;57(5):1239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between March 1992 and January 1996, 39 patients with T1 (32 patients) and T2 breast cancers received 37.2 Gy in 10 fractions (b.i.d.) over 1 week prescribed to a volume encompassing the surgical clips.
  • Thirteen received adjuvant tamoxifen, and 4 received chemotherapy.
  • One of the 2 patients had a 1-mm microscopic margin at initial diagnosis; the recurrence was a 3.5-mm microscopic focus of duct carcinoma in situ.
  • The other patient had a 1.5-cm, high-grade infiltrating mammary carcinoma with no residual at wider resection at first diagnosis; the 5-mm invasive recurrence was also of high grade.
  • Four women developed invasive recurrences at least 1.6 cm or more from the lumpectomy site (out-of-field recurrences).
  • Two of these women had gross multifocal recurrences with two cancers in each patient; 1 of the 2 patients had an extensive intraductal component at initial diagnosis.
  • Of 17 patients who received adjuvant systemic therapy, only 1 had a breast recurrence.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Chemotherapy, Adjuvant. Dose Fractionation. Female. Follow-Up Studies. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Pilot Projects. Salvage Therapy. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1214-6 [14630253.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1210-3 [14630252.001]
  • (PMID = 14630257.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gahn G, Barlinn K, Dzialowski I, Puetz V, Kunz A, Hentschel H, Becker U: Combined thrombolysis with abciximab and rtPA in patients with middle cerebral artery occlusion. Acta Neurol Scand; 2010 Jan;121(1):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In patients with acute middle cerebral artery (MCA) occlusion, recanalization rates with intravenous (IV) recombinant tissue plasminogen activator (rtPA) are limited.
  • Aim- We evaluated the feasibility and safety of combined IV thrombolysis with abciximab and reduced dose rtPA in a 3- to 6-h time window.
  • METHODS: We prospectively (March 2002 to February 2005) studied patients with symptomatic MCA occlusion on computed tomography (CT) angiography and absence of major early ischemic changes (EIC) on non-contrast CT (NCCT) within 3-6 h from symptom onset.
  • RESULTS: Of 13 patients, mean age was 62 +/- 11 years, onset-to-treatment time 4.8 +/- 0.9 h and median baseline National Institutes of Health Stroke Scale score 11 (interquartile range 6.5-13.5).
  • CONCLUSIONS: In patients with acute symptomatic MCA occlusion and absence of major EIC on NCCT, combined IV thrombolysis with abciximab and half-standard dose rtPA was feasible and seemed to be safe if applied within 3-6 h from symptom onset.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunoglobulin Fab Fragments / therapeutic use. Infarction, Middle Cerebral Artery / drug therapy. Platelet Aggregation Inhibitors / therapeutic use. Tissue Plasminogen Activator / therapeutic use
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Pilot Projects. Prospective Studies. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. Abciximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074286.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Fab Fragments; 0 / Platelet Aggregation Inhibitors; EC 3.4.21.68 / Tissue Plasminogen Activator; X85G7936GV / abciximab
  •  go-up   go-down


23. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM: Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther; 2005 Aug;5(4):737-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 20-year follow-up results of two pioneering randomized controlled trials demonstrating equal survival after mastectomy and breast-conservation therapy, recent high-quality, evidence-based clinical practice recommendations have been made.
  • Breast-conservation therapy undoubtedly represents substantial progress for a better quality of life for women with early-stage breast cancer.
  • Risk factors for local failure include margin status, young age and an extensive intraductal component.
  • Young age and family history strongly suggest the need for genetic testing before initiation of treatment.
  • Women with BRCA1 or BRCA2 mutations should be informed about the increased risk of contralateral breast cancer and ipsilateral failure after breast-conservation therapy.
  • Bilateral mastectomy should also be offered as a treatment option.
  • There is controversy over whether current effective adjuvant treatment, including chemotherapy and endocrine therapy, beyond appropriate local treatment as surgery and radiotherapy, can improve local control.
  • Instead of debate over whether an ipsilateral tumor after breast-conservation therapy is local recurrence or a new primary cancer by analyzing conflicting data lacking strong evidence, efforts should be focused on reducing this risk irrespective of origin.
  • Selecting women for breast-conservation therapy and achieving margin control can reduce ipsilateral failures.
  • [MeSH-minor] Chemotherapy, Adjuvant. DNA Mutational Analysis. Female. Genes, BRCA1. Genes, BRCA2. Humans. Predictive Value of Tests. Prognosis. Radiotherapy, Adjuvant. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111473.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 68
  •  go-up   go-down


24. Mak HK, Yau KK, Khong PL, Ching AS, Cheng PW, Au-Yeung PK, Pang PK, Wong KC, Chan BP, Alberta Stroke Programme Early CT Score: Hypodensity of &gt;1/3 middle cerebral artery territory versus Alberta Stroke Programme Early CT Score (ASPECTS): comparison of two methods of quantitative evaluation of early CT changes in hyperacute ischemic stroke in the community setting. Stroke; 2003 May;34(5):1194-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The one third middle cerebral artery territory ((1/3) MCA) method and the Alberta Stroke Program Early CT Score (ASPECTS) were used to detect significant early ischemic changes (EIC) on CT brain of acute stroke patients.
  • RESULTS: Significant EIC were present in 11.4% of the scans with the (1/3) MCA method, and 19.4% with ASPECTS.
  • CONCLUSIONS: The (1/3) MCA method was more reliable in detecting significant EIC on CT brain within 6 hours of stroke onset in routine clinical practice, whereas ASPECTS was able to detect significant EIC in a higher proportion of these early scans.
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cohort Studies. Female. Hong Kong / epidemiology. Humans. Infarction, Middle Cerebral Artery / drug therapy. Infarction, Middle Cerebral Artery / epidemiology. Infarction, Middle Cerebral Artery / radiography. Ischemic Attack, Transient / drug therapy. Ischemic Attack, Transient / epidemiology. Ischemic Attack, Transient / radiography. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Prevalence. Prospective Studies. Reproducibility of Results. Single-Blind Method. Thrombolytic Therapy. Time Factors

  • Genetic Alliance. consumer health - Ischemic stroke.
  • Genetic Alliance. consumer health - Stroke 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Stroke. 2003 Oct;34(10):e179; author reply e179 [12970512.001]
  • (PMID = 12690213.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


25. Yafune A, Funatogawa T, Ishiguro M: Extended information criterion (EIC) approach for linear mixed effects models under restricted maximum likelihood (REML) estimation. Stat Med; 2005 Nov 30;24(22):3417-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended information criterion (EIC) approach for linear mixed effects models under restricted maximum likelihood (REML) estimation.
  • In clinical data analysis, the restricted maximum likelihood (REML) method has been commonly used for estimating variance components in the linear mixed effects model.
  • We propose an approach using extended information criterion (EIC), which is a bootstrap-based extension of AIC, for comparing linear mixed effects models with different mean and covariance structures under the REML estimation.
  • [MeSH-minor] Biometry. Growth. Humans. Longitudinal Studies. Platelet Count. Purpura, Thrombocytopenic, Idiopathic / blood. Purpura, Thrombocytopenic, Idiopathic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 John Wiley & Sons, Ltd.
  • (PMID = 16237658.001).
  • [ISSN] 0277-6715
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Ascenzi P, Bocedi A, Bolognesi M, Spallarossa A, Coletta M, De Cristofaro R, Menegatti E: The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci; 2003 Jun;4(3):231-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein.
  • The pancreatic Kunitz inhibitor, also known as aprotinin, bovine basic pancreatic trypsin inhibitor (BPTI), and trypsin-kallikrein inhibitor, is one of the most extensively studied globular proteins.
  • BPTI reacts rapidly with serine proteases to form stable complexes, but the enzyme: inhibitor complex formation may involve several intermediates corresponding to discrete reaction steps.
  • Moreover, BPTI inhibits the nitric oxide synthase type-I and -II action and impairs K+ transport by Ca2+-activated K+ channels.
  • [MeSH-minor] Acute Disease. Amino Acid Sequence. Animals. Cattle. Chymotrypsin / antagonists & inhibitors. Kinetics. Models, Molecular. Pancreatitis / drug therapy. Protein Conformation. Protein Structure, Tertiary. Sequence Homology, Amino Acid. Serine Endopeptidases / metabolism. Thermodynamics. Trypsin Inhibitors / metabolism

  • Hazardous Substances Data Bank. CHYMOTRYPSIN .
  • Hazardous Substances Data Bank. APROTININ .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12769721.001).
  • [ISSN] 1389-2037
  • [Journal-full-title] Current protein & peptide science
  • [ISO-abbreviation] Curr. Protein Pept. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Trypsin Inhibitors; 9087-70-1 / Aprotinin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.1 / Chymotrypsin
  • [Number-of-references] 193
  •  go-up   go-down






Advertisement